A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF)

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

31

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

October 5, 2023

Study Completion Date

November 30, 2026

Conditions
Primary Myelofibrosis
Interventions
DRUG

Fedratinib

Specified dose on specified days

Trial Locations (21)

8528511

Local Institution - 009, Nagasaki

8628655

Local Institution - 020, Kumamoto

392-8510

Local Institution - 021, Suwa

113-8431

Local Institution - 001, Bunkyo-ku

409-3898

Local Institution - 006, Chūō

030-8553

Local Institution - 002, Aomori

113-8677

Local Institution - 004, Bunkyō City

812-8582

Local Institution - 015, Fukuoka

317-0077

Local Institution - 018, Hitachi, Ibaraki

259-1193

Local Institution - 005, Isehara City, Kanagawa

296-8602

Local Institution - 010, Kamogawa

806-8501

Local Institution - 017, Kitakyushu

371-8511

Local Institution - 013, Maebashi

889-1692

Local Institution - 012, Miyazaki

545-8586

Local Institution - 016, Osaka

589-8511

Local Institution - 011, Ōsaka-sayama

003-0006

Local Institution - 014, Sapporo

141-8625

Local Institution - 007, Shinagawa-ku, Tokyo

162-8666

Local Institution - 008, Shinjuku

160-0023

Local Institution - 003, Shinjyuku-ku

760-0017

Local Institution - 019, Takamatsu

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT04446650 - A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring System)- Intermediate or High-risk Primary Myelofibrosis (PMF), Post-polycythemia Vera Myelofibrosis (Post-PV MF), or Post-essential Thrombocythemia Myelofibrosis (Post-ET MF) | Biotech Hunter | Biotech Hunter